We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.63B
AUM Growth
-$447M
Cap. Flow
-$292M
Cap. Flow %
-11.12%
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$30.1M
2
SRRK icon
Scholar Rock
SRRK
+$23.3M
3
THC icon
Tenet Healthcare
THC
+$19.2M
4
FOLD
Amicus Therapeutics
FOLD
+$14M
5
JANX icon
Janux Therapeutics
JANX
+$10.8M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$67.2M
2
HUM icon
Humana
HUM
+$46.9M
3
EXAS
Exact Sciences
EXAS
+$43.4M
4
ALGN icon
Align Technology
ALGN
+$29.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Consumer Staples 1.85%
3 Financials 0.14%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.6B
$141M 5.38%
229,600
-3,900
-2% -$2.29M
ISRG icon
2
Intuitive Surgical
ISRG
$127B
$113M 4.29%
216,000
-54,000
-20% -$28.1M
LLY icon
3
Eli Lilly
LLY
$1.02T
$112M 4.25%
144,500
+2,500
+2% +$2.07M
NBIX icon
4
Neurocrine Biosciences
NBIX
$16.8B
$98.3M 3.74%
720,500
-218,500
-23% -$27M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$95.7M 3.64%
1,096,899
+328,123
+43% +$30.1M
UNH icon
6
UnitedHealth
UNH
$376B
$89M 3.39%
176,000
-118,250
-40% -$67.2M
TVTX icon
7
Travere Therapeutics
TVTX
$5.2B
$86.6M 3.3%
4,973,649
+289,173
+6% +$5.11M
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$10.8B
$81.8M 3.12%
265,212
+2,150
+0.8% +$605K
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.45B
$73.2M 2.79%
1,739,813
-238,459
-12% -$11.8M
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$6.81B
$65.1M 2.48%
1,162,718
-65,375
-5% -$3.61M
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$6.46B
$60.8M 2.32%
1,471,564
-108,924
-7% -$4.54M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$27.5B
$60.3M 2.3%
256,200
+6,200
+2% +$1.63M
PEN icon
13
Penumbra
PEN
$12.7B
$57M 2.17%
240,000
-25,000
-9% -$5.68M
WST icon
14
West Pharmaceutical
WST
$24B
$55.3M 2.1%
168,750
+1,000
+0.6% +$315K
RVMD icon
15
Revolution Medicines
RVMD
$39.9B
$53.1M 2.02%
1,213,257
+203,312
+20% +$10.3M
PHR icon
16
Phreesia
PHR
$663M
$51.3M 1.95%
2,040,000
-242,500
-11% -$5.18M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.06B
$49.1M 1.87%
1,251,859
-64,618
-5% -$2.67M
FRPT icon
18
Freshpet
FRPT
$2.93B
$48.5M 1.85%
327,500
-119,000
-27% -$17.3M
ASND icon
19
Ascendis Pharma A/S
ASND
$16B
$42M 1.6%
305,000
-20,000
-6% -$2.63M
KYMR icon
20
Kymera Therapeutics
KYMR
$8.51B
$41.6M 1.58%
1,034,137
-15,249
-1% -$689K
BSX icon
21
Boston Scientific
BSX
$69.5B
$41.1M 1.56%
460,000
– –
EW icon
22
Edwards Lifesciences
EW
$49.6B
$40.3M 1.54%
545,000
-31,900
-6% -$2.23M
INSM icon
23
Insmed
INSM
$21.4B
$38M 1.45%
550,000
-133,344
-20% -$9.6M
MRUS
24
DELISTED
Merus
MRUS
$37.5M 1.43%
892,549
– –
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.57B
$37.4M 1.42%
307,500
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rock Springs Capital Management held 119 positions worth $2.63B, down 15% from $3.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $292M in Q4 2024, closing 12 positions and reducing 30 holdings. Its most notable exit was Humana, an estimated $46.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Scholar Rock worth $31M.

  • Rock Springs Capital Management's largest Q4 2024 buy was Scholar Rock: 716,782 shares worth $31M.
  • Rock Springs Capital Management added most to Blueprint Medicines in Q4 2024, an estimated $30.1M increase.
  • Rock Springs Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $67.2M.
  • Rock Springs Capital Management fully exited Humana in Q4 2024, selling an estimated $46.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $2.63B portfolio in Q4 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 12 in Q4 2024.
  • Rock Springs Capital Management's portfolio value fell 15% quarter-over-quarter to $2.63B.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.